top of page

FDA approves Klygefa gefurulimab for adults with AChR-positive generalised myasthenia gravis

Writer: nuaxia
nuaxia
1 hour ago
2 min read

The FDA has approved Klygefa, a weekly subcutaneous complement inhibitor, for adults with acetylcholine receptor antibody-positive generalised myasthenia gravis, adding another targeted treatment option for this autoimmune neuromuscular disorder.


The US Food and Drug Administration approved Klygefa (gefurulimab-gaks) on 13 November 2026 for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis, authorising a complement-inhibiting therapy administered by subcutaneous injection with an initial loading dose followed by weekly maintenance dosing.


The medicine carries a boxed warning for serious meningococcal infections and is subject to a restricted Risk Evaluation and Mitigation Strategy, reflecting the infection risks associated with complement inhibition; the approval applies to the specified antibody-positive adult population and is a new medicine authorisation rather than an orphan-drug designation or approval for all myasthenia gravis subtypes.

Field

Content

Article Type

Approvals

Product Brand Name

Klygefa

Active Ingredient

Gefurulimab-gaks

Drug Classification

Complement inhibitor

Regulatory Authority

US Food and Drug Administration

Approval Date

13 November 2026

Regulatory Decision

New medicine approval

Geographic Scope

United States

Therapeutic Area

Neurology

Disease

Generalised myasthenia gravis

Disease Abbreviation

gMG

Approved Population

Adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis

Required Antibody Status

Anti-acetylcholine receptor antibody-positive

Antibody Abbreviation

AChR

Administration Route

Subcutaneous injection

Initial Dosing

Loading dose

Maintenance Dosing

Weekly

Therapeutic Mechanism

Complement inhibition

Boxed Warning

Serious meningococcal infections

Risk Management Requirement

Restricted Risk Evaluation and Mitigation Strategy

Risk Management Abbreviation

REMS

Infection Safety Concern

Meningococcal infection risk associated with complement inhibition

Approved for All Myasthenia Gravis Subtypes

No

Orphan-Drug Designation Only

No

Regulatory Status

FDA-approved medicine

What Happened

The FDA approved Klygefa for adults with AChR antibody-positive generalised myasthenia gravis.

Why It Matters

The authorisation expands the range of targeted treatment options for eligible adults with this autoimmune neuromuscular disease.

Clinical Significance

The medicine provides a subcutaneous complement-inhibiting treatment option with weekly maintenance administration.

Regulatory Significance

Represents a new FDA medicine approval for a defined antibody-positive myasthenia gravis population.

Safety Significance

The boxed warning and restricted REMS reflect the potentially serious consequences of meningococcal infection.

Population Clarification

The approved indication is limited to adults with AChR antibody-positive generalised disease.

Key Takeaway

Klygefa has received FDA approval for AChR-positive generalised myasthenia gravis in adults, subject to significant infection-related precautions.

What to Watch

Commercial availability, clinical adoption, treatment access, vaccination and risk-management implementation, and real-world safety.

Primary Source

US Food and Drug Administration

Primary Source URL

https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

Submitted Source

NeurologyLive

Submitted Source URL

https://www.neurologylive.com/view/fda-approves-gefurulimab-generalized-myasthenia-gravis

Relevant Date

13 November 2026


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page